Last updated: 2026-09-05 23:31:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Orchestra BioMed Holdings, Inc. (OBIO) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $5.07, with a market capitalization of $297.52M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.20 to $5.78. This page covers its latest market performance, valuation, price trends and company information.
$297.52M | |
$4.71 | |
$23.39 | |
$2.20 | |
$4.74 | |
457.37K | |
-- | |
-- | |
$5.78 | |
$2.20 | |
-- | |
-- |
Orchestra BioMed Holdings, Inc. (OBIO) last closed at $4.74 as of 2026-09-04 23:31:00, unchanged from the previous close of $4.74.
During the latest regular trading session, OBIO traded between $2.20 and $23.39, with a volume of 457.37K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Orchestra BioMed Holdings, Inc. (OBIO) moved from $5.23 to $5.07, representing a decline of 3.04% ($0.16).
The stock traded between $4.69 and $5.13 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 272.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.2%
OBIO is currently trading at $5.07, placing it 80.2% of the way from its 52-week low of $2.20 to its 52-week high of $5.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 86 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Orchestra BioMed Holdings, Inc. (OBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.